Advertisement

Immunosuppressive therapy for cardiac transplantation

  • Stuart W. Jamieson
  • Philip E. Oyer
  • Edward B. Stinson
  • Norman E. Shumway
Chapter
Part of the Developments in Surgery book series (DISU, volume 5)

Abstract

The immunosuppression of cardiac transplantation recipients is required indefinitely. Acute rejection episodes occur in most patients, and must be identified early and treated effectively. Acute rejection is seen most frequently during the first three postoperative months with both ‘conventional therapy’ and patients treated with cyclosporine. With standard immunosuppression, 90% of patients experience at least one rejection episode during this interval; with cyclosporine the incidence of this is somewhat less. The frequency of acute rejection declines substantially after 12 months (one episode per 748 patient days, compared to 1 per 35 patient days during the first three months) (1).

Keywords

Acute Rejection Cardiac Transplantation Antithymocyte Globulin Acute Rejection Episode Cyclosporine Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jamieson SW, Bieber CP, Oyer PE: Immunosupression in Clinical Cardiac Transplantation. In: Immunosuppressive Therapy. (Salaman JR ed) MTP Press, pp 177-199, 1981.Google Scholar
  2. 2.
    Caves PK, Stinson EB, Billingham ME, Shumway NE: Percutaneous Transvenous Endomyocardial Biopsy in Human Heart Recipients. Ann Thorac Surgery 16: 325, 1973.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague 1984

Authors and Affiliations

  • Stuart W. Jamieson
  • Philip E. Oyer
  • Edward B. Stinson
  • Norman E. Shumway

There are no affiliations available

Personalised recommendations